Insider · CIK 0001856708
Dipti Amin
Files at LCTX (Lineage Cell Therapeutics, Inc.). First filing -, latest -.
In brief
Dipti Amin files SEC Form 4 as director at LCTX (Lineage Cell Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Dipti Amin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jul 1, 2025 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jul 2, 2025 |
Questions about Dipti Amin
Answered from the filings on this page, as of the latest one.
Is Dipti Amin buying or selling?
Dipti Amin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Dipti Amin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dipti Amin has 0.
Where does Dipti Amin file Form 4?
Dipti Amin has filed Form 4 at LCTX (Lineage Cell Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.